Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24408083 | 0.95 | TOP2A (0.38) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL22512575 | 0.91 | HSD17B3 (0.48) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL24871031 | 0.88 | HSD17B3 (0.37) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL27422299 | 0.87 | KDM4E (0.36) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL19387290 | 0.86 | KDM4E (0.48) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL21366311 | 0.86 | KMT2A (0.39) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL24349696 | 0.86 | NOTUM (0.46) | TOP2AHSD17B3MAP3K5NOTUMCYP2C9 | |
| SCHEMBL24701748 | 0.85 | KDM4E (0.37) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL19604395 | 0.85 | HSD17B3 (0.35) | ALDH1A1MAPTKDM4ELMNATSHR | |
| SCHEMBL23962032 | 0.85 | TSHR (0.38) | ALDH1A1MAPTKDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372528-A1 | GLYCOCONJUGATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230372528-A1 | GLYCOCONJUGATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230201365-A1 | MODIFIED CD20 ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230201364-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230201364-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230183331-A1 | MODIFIED TNF-ALPHA ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183331-A1 | MODIFIED TNF-ALPHA ANTIBODIES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230181754-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230181754-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20210252157-A1 | MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-10745700-B2 | Nucleic acid conjugate | KYOWA KIRIN CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| US-20190175750-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | ADVANCED PROTEOME THERAPEUTICS INC. | 2019-06-13 | — | — | US | disclosed |
| US-20190055558-A1 | NUCLEIC ACID CONJUGATE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | IL18, CD74, IL2 | ALDH1A1 3165/4885MAPT 3580/4885KDM4E 4473/4885 |
| US-10745700-B2 | Nucleic acid conjugate | SLC29A1, NSUN2, H1-2 | ALDH1A1 367/4885MAPT 2840/4885KDM4E 4314/4885 |
| US-20230201364-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | CD2BP2, CD47, BCR | ALDH1A1 3518/4885MAPT 1742/4885KDM4E 2451/4885 |
| US-20230372528-A1 | GLYCOCONJUGATES | CD22, SIGLEC7, CD47 | ALDH1A1 1591/4885MAPT 2047/4885KDM4E 2462/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | ALDH1A1 3285/4885MAPT 3987/4885KDM4E 3165/4885 |
| US-20230201365-A1 | MODIFIED CD20 ANTIBODIES AND USES THEREOF | CD209, CD22, CD47 | ALDH1A1 4615/4885MAPT 4100/4885KDM4E 3471/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | ALDH1A1 1481/4885MAPT 2902/4885KDM4E 2938/4885 |
| US-20230181754-A1 | MODIFIED CHECKPOINT INHIBITORS AND USES THEREOF | PDCD1LG2, CD274, PDCD1 | ALDH1A1 3313/4885MAPT 2796/4885KDM4E 2166/4885 |
| US-20190175750-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | PTMS, SRMS, ACP1 | ALDH1A1 3789/4885MAPT 592/4885KDM4E 3594/4885 |
| US-20230183331-A1 | MODIFIED TNF-ALPHA ANTIBODIES AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 3816/4885MAPT 2494/4885KDM4E 4509/4885 |
| US-20210252157-A1 | MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF | IL2, IL2RA, IL6ST | ALDH1A1 2440/4885MAPT 4291/4885KDM4E 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.